Insempra raised $20M Series A to advance bio-based alternatives

This financing round follows an initial $15 million Seed round in 2021 and will facilitate Insempra's technology scale-up, scouting, development, and manufacturing capabilities.



Insempra, a German biotech company, has successfully raised $20 million in Series A financing. The funding will propel Insempra’s mission to pioneer bio-based alternatives in manufacturing, enabling businesses to shift from harmful chemicals to superior natural ingredients at an industrial scale.

The Series A round saw participation from existing investors EQT Ventures, BlueYard Capital, Possible Ventures, Taavet Sten, and Acequia Capital, along with new investors including Henkel dx Ventures, Bayern Kapital, and Alante Capital. Ted Persson, Partner at EQT Ventures, highlighted Insempra’s potential to revolutionize industrial manufacturing processes and drive market traction for its products.

Insempra specializes in creating naturally superior products through advanced biological manufacturing processes. By designing and building ingredients with atomic precision, the company offers better solutions than agriculturally and petrochemically sourced oils and materials. Its focus spans various industries, including cosmetics, food, polymers, textiles, and functional ingredients like antioxidants and preservatives.

Jens Klein, founder and CEO of Insempra, expressed gratitude for the investors’ support and emphasized the company’s commitment to developing sustainable materials in collaboration with nature.

Related Stories